Genomic Health observed a robust share price movement as compared to the Medical-Biomed/Genetics sub-industry trend in majority of the last six months. The company also recorded a strong revenue trend in the last five years. Genomic Health ended third-quarter 2016 on a disappointing note with both the top and the bottom line missing the Zacks Consensus Estimate. We are concerned about the company’s rising operating expenses as well. Additionally, fluctuations in the price of the marketable security continued to hamper the stock, which is expected to remain for the rest of 2016. However, on a positive note, despite a huge rise in cost of sales, the gross margin improved in the third quarter. Genomic Health continues to experience strong test volume as well as revenue growth, across its global region.